替比夫定对HBeAg阳性慢性乙型肝炎患者治疗两年回顾性分析

A retrospective analysis o n patients with HBeAg -positive chronic hepatitis B treated with telbivudine for two years

目的:回顾性分析替比夫定治疗HBeAg阳性慢性乙型肝炎(CHB)患者两年的临床疗效和安全性。方法:纳入HBeAg阳性CHB患者,随机分为两组,分别使用替比夫定、阿德福韦酯治疗两年,每3～6个月进行HBVDNA、ALT及HbeAg检测,并进行安全性评估。结果:共纳入67例HBeAg阳性CHB患者(替比夫定组33例、阿德福韦酯34例),治疗12和24个月范围,其HBVDNA不可测,ALT复常以及12个月范围HBeAg血清转换两组患者比较无显著性差异,而治疗24个月范围替比夫定组患者HBeAg血清转换为42.4%(14/33)高于阿德福韦酯组17.6%(6/34)(P<0.05),且两组安全性良好。结论:替比夫定较阿德福韦酯具有更显著抗病毒疗效。两组均具有良好的安全性和耐受性。

Objective：To retrospective analyze on the clinical efficacy and safety of patients with HBeAg-positive chronic hepatitis B treated with telbivudine for two years. Methods：We divided patients with HBeAg-positive chronic hepatitis B into two groups by random grouping, One group was treated with telbivudine for two years, while the other with adefovir dipivoxil for two years. We tested their HBV-DNA, ALT, and HbeAg level for every 3-6 months. And then we evaluated the drug safety. Results：There were 67 patients （33 in group one and 34 in group two）. There were no significant difference in the change of the level of HBV-DNA,ALT and HBeAg during treatment months of 12 and 24. The serum HBeAg conversion rate in group treated with telbivudine （42.4%） was higher than the group treated with adefovir dipivoxi（l17.6%）during the 24 treatment months（P0.05）. Both of the groups had good drug safety. Conclusion：Telbivudine had better antiviral effects than adefovir dipivoxil. Both groups had good safety and tolerability.